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Objectives. This study attempted to determine whether long- 
term treatment with cyclosporine A in rats affects cardiac betat- 
adrenoceptors and whether this can be prevented by angiotensin- 
converting enzyme inhibitors or calcium-entry blocking agents. 
Background. In the transplanted human heart the density of 
betal-adrenoceptors decreases with time after transplantation, 
whereas that of beta2-adrenoceptors does not. Because heart 
transplant recipients are treated with cyclosporine A, we studied 
whether administration of cyclosporine A in rats might cause this 
betal-adrenoceptor downregulation. 
Methods. We performed two studies. First, we treated groups of 
10 male normotensive Wistar rats orally with 30 mg/kg body 
weight per day of cyclosporine A, 10 mg/kg per day of enalapril 
and 60 mg/kg per day of diltiazem, alone or in combination, for 6 
weeks each. Second, we treated groups of 15 male normotensive 
Wistar rats orally with 15 mg/kg per day of cyclosporine A and 
10 mg/kg per day of lisinopril, alone or in combination, for 6 weeks 
each. At the end of each treatment regimen, cardiac beta- 
adrenoceptor density and subtype distribution were assessed by 
( - )  - [ 12si] iodocyanopindolol binding. 
Results. Both doses of cyclosporine A caused a significant 
decrease in cardiac betal-adrenoceptor density without affecting 
beta2-adrenoceptor density. Although diltiazem and the 
angiotensin-converting enzyme inhibitors alone did not affect 
cardiac beta-adrenoceptors, they prevented the cyclosporine 
A-induced downregulation fbeta~-adrenoceptors. 
Conclusions. In normotensive Wistar rats, cyclosporine A 
causes a significant decrease in cardiac betal-adrenoceptors with- 
out affecting beta2-adrenoceptors. This can be prevented by dilti. 
azem or angiotensin-converting enzyme inhibitors. In heart rans- 
plant recipients, who undergo long-term treatment with 
cyclosporine A, there is a very similar betal-adrenoceptor d wn- 
regulation with time after transplantation. Thus, administration 
of cyclosporine A may cause these beta-adrenoceptor subtype 
alterations. 
(J Am CoU Cardioi 1995;25:761-7) 
With the introduction of the immunosuppressive agent cyclo- 
sporine A, graft survival in organ transplantation has markedly 
improved (1). However, anumber of unwanted side effects are 
associated with cyclosporine A treatment, including tremor, 
tachycardia (2,3), nephrotoxicity (4) and dysfunction of endo- 
thelial and smooth muscle cells in the arterial wall (5,6), that 
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might be involved in the development of hypertension and 
renal failure (7,8). 
We recently observed that 7 weeks of treatment with 
cyclosporine A (20 mg/kg body weight orally) in young spon- 
taneously hypertensive rats induced a marked increase in the 
elevated blood pressure (9,10) and caused a selective down- 
regulation of cardiac betal-adrenoceptors without altering 
cardiac beta2-adrenoceptors (11). Very similar decreases 
in betat-adrenoceptors without any alteration in beta2- 
adrenoceptors are found in the transplanted human heart with 
increasing time after transplantation (12-14). Because heart 
transplant recipients undergo long-term treatment with cyclo- 
sporine A, we hypothesized that cyclosporine A might be the 
cause of the cardiac betaa-adrenoceptor d wnregulation. We 
t erefore studied the effects of cyclosporine A (30 and 
15 mg/kg orally for 6 weeks) on cardiac beta-adrenoceptors in 
normotensive Wistar rats, which do not develop hypertension 
during cyclosporine A treatment (10). Furthermore, cyclospo- 
rine A in the rat increases afferent and efferent sympathetic 
nerve activity and activates the renin-angiotensin system, as 
demonstrated by increased renin release (15 [and references 
©1995 by the American Collegc of Cardiology 0735-1097/95/$9.50 
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therein]). We therefore also studied the effects of angiotensin- 
converting enzyme inhibitors on possible cyclosporine A- 
induced changes in cardiac beta-adrenoceptor subtypes. Fi- 
nally, because calcium-entry blocking agents have been found 
to be very protective against cyclosporine A-induced renal 
ischemic injury (16-18) and are therefore frequently used in 
renal transplant recipients (19,20), we also studied the effects 
of diltiazem on possible cyclosporine A effects on cardiac 
beta-adrenoceptor subtypes. 
Methods  
Study protocol. We performed two studies. First study. 
Eighty male Wistar rats were randomly assigned to six groups. 
In addition to their standard iet (Altromin, Altromin GmbH 
& Co KG, Lange, Germany), the rats received aily treatment 
with one of the following: 1 ml of olive oil (n = 20), 30 mg/kg 
per day of cyclosporine A dissolved in olive oil (n = 20), 
10 mg/kg per day of the angiotensin-converting enzyme- 
inhibitor enalapril dissolved in distilled water (n = 10), 
60 mg/kg per day of the calcium-entry blocker diltiazem 
dissolved in distilled water (n = 10), cyclosporine A plus 
diltiazem (n = 10) or cyclosporine A plus enalapril (n = 10) 
administered through an oral gastric tube for 6 weeks. Two rats 
in the cyclosporine A group, two rats in the cyclosporine A plus 
diltiazem group and four rats in the cyclosporine A plus 
enalapril group died during the treatment period. On the basis 
of the data obtained with these treatment regimens (see 
Results), we decided to perform a second study. 
Second study. Sixty male adult Wistar rats were treated 
with one of the following: 1 ml of olive oil (n = 15), 15 mg/kg 
per day of cyclosporine A (n = 15), 10 mg/kg per day of the 
angiotensin-converting e zyme inhibitor lisinopril dissolved in 
distilled water (n = 15) or cyclosporine A plus lisinopril (n = 
15) orally for 6 weeks, as described in the first study. 
Twenty-four hours after the last treatment, the rats were 
anesthetized with ether; blood pressure was measured inva- 
sively in the abdominal orta; and 5 ml of blood was withdrawn 
from the abdominal orta for laboratory tests. Blood levels of 
cyclosporine A were measured by a fluorescence-polarizing 
immunoassay used for routine drug monitoring in heart rans- 
plant recipients (Abbott Laboratories). Laboratory tests for 
renal function (serum creatinine and serum nitrogen urea 
levels) were performed with an automatic analyzer (BM/ 
Hitachi System 717, Boehringer, Mannheim, Germany). After 
the rats had been exsanguinated, the aortas and hearts were 
rapidly excised. The aortas were used to study the effects of 
cyclosporine A on vascular function (18,21,22), and the hearts 
were cleaned of connective tissue and quickly frozen in liquid 
nitrogen. 
Beta-adrenoceptor determination. For preparation of 
membranes, the hearts were minced with scissors and homog- 
enized with a glass-Teflon homogenizer (Braun, Melsungen, 
Germany) with 10 strokes at 1,500 rpm. The homogenate was 
diluted up to 50 ml with buffer and centrifuged at 1,000 g for 
15 rain. Pellets were discarded, and the supernatant was 
filtered through four layers of medical gauze and centrifuged at
21,000 g for 45 rain. Final pellets were resuspended in incuba- 
tion buffer (10 retool/liter of Tris, 154 retool/liter of sodium 
chloride and 0.01% ascorbic acid at a pH of 7.4), rehomog- 
enized with six strokes at 800 rpm and diluted to 100 ml/g of 
wet weight. The protein concentration f the final membrane 
preparation was assessed by the method of Bradford (23) using 
bovine immunoglobulin G as standard. 
Beta-adrenoeeptor density was assessed by (-)-[125I] iodocya- 
nopindolol (ICYP) binding at six concentrations of ICYP ranging 
from 10 to 200 pmol/liter (ICYP specific activity 2,000 Ci/mmol, 
New England Nuclear, Dreieich, Germany). An aliquot of the 
membrane suspension (150/~1) was incubated with ICYP in a 
final volume of 250 ~1 for 90 rain at 37°C. Incubation was stopped 
by adding 10 ml of incubation buffer to the entire incubation 
mixture, followed by rapid vacuum filtration over Whatman GF/C 
glass fiber filters. Each filter was washed with an additional 10 ml 
of incubation buffer, and the remaining radioactivity was deter- 
mined in a Beckman gamma counter at an efficiency of 80%. 
Nonspecific binding of ICYP was defined as the radioactivity 
bound in the presence of a high concentration f (-+)-CGP 12177 
(1 ~mol/liter). Specific binding was defined as total binding minus 
nonspecific binding and usually amounted to >80% at 20 pmol/ 
liter of ICYP. 
To determine the relative amount of beta 1- and betaz-adre- 
noceptors, membranes were incubated with ICYP (100 pmol/ 
liter) in the presence or absence of eight concentrations (range 
10-10 to 10 -3 mol/liter) of the highly selective betal-adrenoceptor 
antagonist CGP 20712 A (24), and specific binding was deter- 
mined as described earlier. Details have been described else- 
where (25). The CGP 20712 A competition curves were analyzed 
by the iterative curve-fitting program InPlot (GraphPad soft- 
ware). Statistical nalysis was performed using the F ratio test to 
measure the goodness of fit of the competition curves for either 
one or two sites. 
All chemicals used in this study were of the highest purity 
grade commercially available. 
Statistical evaluations. Results are presented as mean 
value _+ SEM of n experiments. The equilibrium dissociation 
constant (KD) and the maximal number of binding sites (Bmax) 
for ICYP were calculated from plots according to Scatchard 
(26). The significance of differences in the number of binding 
sites in two different groups was estimated by an unpaired 
two-tailed Student t test; p < 0.05 was considered significant. 
Results  
Effects of 30 mg/kg per day of cyclosporine A. After 6 
weeks of treatment with cyclosporine A (30 mg/kg per day), 
blood levels were between 3,000 and 5,000 ng/ml (Table 1). In 
the cyclosporine A-treated rats, mean blood pressure was 
unchanged, but weight gain was significantly retarded. In 
addition, serum nitrogen urea levels were significantly ele- 
vated, and serum creatinine levels showed a tendency to 
increase. Enalapril and diltiazem did not prevent retardation 
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Table 1. Laboratory Tests in Rats After 6 Weeks of Treatment With 30 mg/kg per Day of Cyclosporine A 
Diltiazem Enalapril 
Control CSA Diltiazem Enalapril + CSA + CSA 
(n = 20) (n = 18) (n = 10) (n = 10) (n = 8) (n = 6) 
Body weight (g) 
Before treatment 358 _+ 5 316 ± 7 317 ± 10 335 _+ 10 324 ± 7 328 ± 7 
End of treatment 402 _+ 9 306 +_ 15" 386 + 7 383 _+ 13 323 ± 13' 343 -+ 5 
Mean blood pressure (mm Hg) 81 + 4 81 _+ 3 80 _+ 5 76 ± 3 77 - 5 75 -+ 6 
CSA blood levels (ng/ml) 5,313 _+ 913 5,615 ± 888 3,180 _+ 610 
Serum urea (mg/100 ml) 47.6 _+ 1.7 82.2 _+ 4.5* 47.1 ± 1.7 45.0 +_ 2.0 86.3 -- 13.5" 80.0 -+ 5.1' 
Serum creatinine (mg/100 ml) 0.7 +_ 0.02 0.8 _+ 0.02 0.6 -+ 0.01 0.6 -+ 0.02 0.7 ± 0.1 0.8 -+ 0.1 
*p < 0.01 versus olive oil-treated rats (Control). Data presented are mean value _+ SEM. CSA = cyclosporine A. 
in weight gain and increase in serum nitrogen urea levels 
(Table 1). 
Cyclosporine A significantly decreased cardiac beta- 
adrenoceptor density by -20 to 25% (Fig. 1), a result of a 
selective decrease in betat-adrenoceptors but no significant 
alteration in beta2-adrenoceptors (Fig. 1). Enalapril alone did 
not affect rat cardiac beta-adrenoceptor density or subtype 
distribution (Fig. 2). However, administration of enalapril in 
addition to cyclosporine A completely prevented the cyclospo- 
rine A-induced decrease in betat-adrenoceptor density (Fig. 
2). 
Similar to enalapril, administration of the calcium-entry 
blocker diltiazem alone did not affect cardiac beta-adrenoceptor 
density or subtype distribution (Fig. 3) but completely prevented 
the cyclosporine A-induced decrease in cardiac beta 1- 
adrenoceptor density (Fig. 3). 
Effects of 15 mg/kg per day of cyclosporine A. In the first 
study, the 30-mg/kg cyclosporine A dose resulted in markedly 
higher blood levels of cyclosporine A compared with the 
therapeutic range used in humans (27). Because the observed 
changes in cardiac beta-adrenoceptors might express toxic side 
effects of cyclosporine A, we therefore decided to study a 
15-mg/kg per day dose of cyclosporine A for 6 weeks that 
Figure 1. Effects of 6 weeks of treatment with cyclosporine A (CSA) 
(30 mg/kg per day orally) on cardiac beta-adrenoceptors in rats. 
Ordinate = total beta-, betas- and beta2-adrenoceptor density in 
cardiac membranes in fmol of ICYP specifically bound/mg of protein. 
Data are mean value _+ SEM (number of experiments); dissociation 
constant values for ICYP are 8.3 _+ 1.1 pmol/liter (Control) and 8.9 _+ 
1.4 pmol/liter (cyclosporine A). Control = olive oil-treated rats; 
ICYP = (-)-[aesI]iodocyanopindolol. 
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would result in more therapeutically relevant blood levels 
(-400 to 500 ng/ml) (Table 2). Moreover, in this study we used 
lisinopril as the angiotensin-converting enzyme inhibitor to 
determine whether it might have beta-adrenoceptor-protecting 
effects in the rat similar to those in the failing human heart (28). 
As shown in Table 2, the 15-mg/kg dose of cyclosporine A 
did not cause weight gain retardation or increases in serum 
creatinine or nitrogen urea levels. Serum nitrogen urea was 
increased only in the cyclosporine A plus lisinopril group 
(Table 2). 
Treatment with 15 mg/kg of cyclosporine A caused only a 
mild reduction in rat cardiac beta-adrenoceptor density (p = 
NS) (Fig. 4). However, after 6 weeks of treatment with 
Figure 2. Effects of 6 weeks of treatment with enalapril (10 mg/kg per 
day orally) (top) or cyclosporine A (CSA) (30 mg/kg per day) plus 
enalapril (10 mg/kg per day orally) (bottom) on cardiac beta- 
adrenoceptors in rats. Ordinates = total beta-, beta 1- and beta 2- 
adrenoceptor density in cardiac membranes in fmol of ICYP specifi- 
cally bound/mg of protein. Data are mean value _+ SEM (number of 
experiments); dissociation constant values for ICYP are 9.1 _+ 
0.9 pmol/liter (enalapril) and 8.8 -+ 1.7 pmol/liter (enalapril plus 
cyclosporine A). Other abbreviations a in Figure 1. 
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Figure 3. Effects of 6 weeks of treatment with diltiazem (60 mg/kg per 
day orally) (top) or cyclosporine A (CSA) (30 mg/kg per day) plus 
diltiazem (60 mg/kg per day orally) (bottom) on cardiac beta- 
adrenoceptors in rats. Ordinates = total beta-, beta 1- and beta 2- 
adrenoceptor density in cardiac membranes in final of ICYP specifi- 
cally bound/mg of protein. Data are mean value _+ SEM (number of 
experiments); dissociation constant values for ICYP are 7.9 -+ 
1.2 pmol/liter (diltiazem) and 8.4 -+ 0.8 pmol/liter (diltiazem plus 
cyclosporine A). Other abbreviations as in Figure 1. 
cyclosporine A, cardiac betal-adrenoceptor density was signif- 
icantly reduced, whereas beta2-adrenoceptor density was not 
affected (Fig. 4). Lisinopril alone did not affect cardiac beta- 
adrenoceptor density or subtype distribution (Fig. 5). How- 
ever, lisinopril completely prevented the cyclosporine 
A-induced decrease in cardiac betal-adrenoceptor density 
(Fig. 5). 
Discuss ion  
Cyclosporine A causes selective downregulation of betal- 
adrenoceptors in the rat heart. In the present study, 6 weeks 
of treatment with cyclosporine A in normotensive Wistar rats 
caused aselective downregulation ofcardiac beta l-adrenoceptors 
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Figure 4. Effects of 6 weeks of treatment with cyclosporine A (CSA) 
(15 mg/kg per day orally) on cardiac beta-adrenoceptors in rats. 
Ordinates = total beta-, beta1- and betaz-adrenoceptor density in 
cardiac membranes in final of ICYP specifically bound/rag of 
protein. Data are mean value + SEM (number of experiments); 
dissociation constant values for ICYP are 11.4 _+ 2.1 pmol/liter 
(control) and 12.1 _+ 1.9 pmol/liter (cyclosporine A treated). Other 
abbreviations as in Figure 1. 
but no significant alteration in cardiac beta2-adrenoceptors. This 
alteration occurred not only with the high dose of 30 mg/kg per 
day of cyclosporine A, resulting in very high blood levels (3,000 to 
5,000 ng/ml), but with the lower dose of 15 mg/kg per day as well, 
resulting in blood levels (-500 ng/ml) in the therapeutic range of 
c3'dosporine A given the finding that in rats higher doses of 
c2¢closporine A are needed to prevent rejection of transplanted 
organs than in humans [29]. Thus, the decrease in beta 1- 
adrenoceptor density was not an expression of toxic side effects of 
cyctosporine A and also occurred in therapeutically relevant 
doses. 
We previously showed (11) in young spontaneously h per- 
tensive rats that treatment with cyclosporine A (20 mg/kg per 
day for 7 weeks) augmented blood pressure and caused a 
decrease in cardiac betal-adrenoceptor density but no change 
in beta2-adrenoceptor density. One could argue that this 
decrease in betal-adrenoceptor density is not caused by cyclo- 
sporine A but is due to the finding that in several forms of 
experimental hypertension, severe levation of blood pressure 
is often associated with a selective downregulation of cardiac 
Table 2. Laboratory Tests in Rats After 6 Weeks of Treatment With 15 mg/kg per Day of 
Cyclosporine A
Lisinopril 
Control CSA Lisinopril + CSA 
(n = 15) (n = 15) (n = 15) (n = 15) 
Body weight (g) 
Before treatment 260 _+ 11 279 _+ 12 253 + 7 309 - 18 
End of treatment 370 + 14 381 + 11 346 _+ 8 366 _+ 12 
CSA blood levels (ng/ml) 506 _+ 96 431 _+ 50 
Serum urea (mg/100 ml) 40.9 _+ 1.5 45.0 + 6.4 48.1 - 1.6 94.9 _+ 6.4* 
Serum creatinine (rag/t00 ml) 0.52 -+ 0.02 0.56 -+ 0.03 052 -+ 0.04 0.59 -+ 0.02 
*p < 0.01 versus olive oil-treated rats (Control). Data presented are mean value _+ SEM. CSA = cyclosporine A.
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Figure 5. Effects of 6 weeks of treatment with lisinopril (10 mg/kg per 
day orally) (top) or cyclosporine A (CSA) (15 mg/kg per day) plus 
lisinopril (10 mg/kg per day orally) (bottom) on cardiac beta- 
adrenoceptors in rats. Ordinates = total beta-, beta1- and beta2- 
adrenoceptor density in cardiac membranes in fmol of ICYP specifi- 
cally bound/rag ofprotein. Data are mean value _+ SEM (number of 
experiments); dissociation constant values for ICYP are 10.9 _+ 
2.0 pmol/liter (lisinopril) and 12.2 _+ 1.6 pmol/liter (lisinopril plus 
cyclosporine A). Other abbreviations as in Figure 1. 
betal-adrenoceptors (for review, see ref. 30). However, in the 
present study, both doses of cyclosporine A also caused a 
similar decrease in betal-adrenoceptor density in normoten- 
sive rats, although long-term treatment with cyclosporine A
does not increase blood pressure in normotensive rats (10) 
(Table 1). Thus, hypertension i itself is not the cause of the 
cyclosporine A-induced decrease in betai-adrenoceptor den- 
sity. 
However, in the present study we assessed only cardiac 
beta-adrenoceptor density, not cardiac G-protein(s) or adeny- 
late cyclase activity. Thus, it remains to be elucidated whether 
the decrease in cardiac betal-adrenoceptor density after long- 
term cyclosporine A treatment is accompanied by functional 
changes. Moreover, the rat heart shows regional distribution of 
beta-adrenoceptors, andthe total number of beta 1- and beta2- 
adrenoceptors i  higher in the atrioventricular conducting 
system than in myocardium (31-33). In the present study we 
assessed beta-adrenoceptors in the whole rat heart only. Thus, 
we cannot exclude the possibility that the effects of cyclospo- 
rine A on beta-adrenoceptor subtypes (i.e., downregulation f
betal-adrenoceptors with no change in beta2-adrenoceptors) 
might vary regionally. 
The mechanism underlying the decrease in cardiac beta1- 
adrenoceptor density after long-term treatment with cyclospo- 
fine A is not understood at present. However, it is well known 
that cyclosporine A in rats causes an increase in the activity of 
the sympathetic as well as the renin-angiotensin system (15). 
Both are closely interrelated. Thus, increases in sympathetic 
activity enhance renin release in the rat by means of beta l- 
adrenoceptor stimulation (34), and angiotensin II can enhance 
noradrenaline r lease through activation of presynaptic angio- 
tensin II receptors (35). Because an increase in sympathetic 
activity is accompanied by an increased release of noradrena- 
line, it is possible that in cyclosporine A-treated rats cardiac 
beta-adrenoceptors undergo long-term exposure to increased 
noradrenaline concentrations. However, noradrenaline is a 
selective betaa-adrenoceptor agonist (36); for example, in rats 
harboring a noradrenaline-secreting pheochromocytoma, nor- 
adrenaline causes a selective downregulation of beta 1- 
adrenoceptors but no change in beta2-adrenoceptors in various 
tissues (37,38). Moreover, long-term infusion of noradrenaline 
in rabbits has been shown (39) to induce selective down- 
regulation of betaa-adrenoceptors without affecting beta 2- 
adrenoceptors in various tissues. Thus, it is possible that in 
cyclosporine A-treated rats, increased sympathetic a tivity (by 
means of enhanced [locally?] released noradrenaline) causes 
the selective downregulation of cardiac betal-adrenoceptors. 
Angiotensin-eonverting enzyme inhibitors prevent cyclo- 
sporine A-induced betal-adrenoceptor downregulation in the 
rat heart. In support of this hypothesis i the finding that in 
the present study, angiotensin-converting enzyme inhibitors 
prevented the cyclosporine A-induced downregulation f car- 
diac betal-adrenoceptors. As previously discussed, the sympa- 
thetic nervous and renin-angiotensin systems are closely inter- 
related. Thus, antagonization f one system should inhibit the 
other. For example, it has been shown (40-42) that 
angiotensin-converting e zyme inhibitors reduce angiotensin 
II-facilitated release of noradrenaline in animal models. Ac- 
cordingly, the most likely explanation for the angiotensin- 
converting enzyme inhibitor-induced prevention of cardiac 
betal-adrenoceptor d wnregulation caused by cyclosporine A 
treatment is that enalapril and lisinopril reduce the cyclospo- 
rine A-induced activation of sympathetic activity, thereby 
preventing betal-adrenoceptor d wnregulation. 
In favor of this assumption are results obtained in guinea 
pigs, where captopril partially prevented cardiac beta- 
adrenoceptor downregulation i duced by long-term isoprena- 
line treatment (43), and in patients with chronic heart failure, 
where lisinopril restored the reduced cardiac beta-adrenoceptor 
density to pretreatment levels (28). In the latter study, lisinopril 
increased cardiac beta-adrenoceptor density in only those pa- 
tients with high coronary sinus noradrenaline l vels (i.e., express- 
ing high sympathetic drive) but not in those exhibiting nearly 
normal noradrenaline levels. This strengthens the idea (see 
earlier) that angiotensin-converting e zyme inhibitors might pre- 
vent (or at least attenuate) beta-adrenoceptor d wnregulation by 
means of antagonizing sympathetic activity. 
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The calcium entry blocker diltiazem prevents cyclosporine 
A-induced betaradrenoceptor downregulation in the rat 
heart. In the present study the calcium entry blocker diltiazem 
also prevented cyclosporine A-induced betal-adrenoceptor 
downregulation. This result was not brought about by the 
direct effect of diltiazem on cardiac beta-adrenoceptors be-
cause in the rat heart (present study) and in the nonfailing 
(44-46) and failing (46) human heart, calcium entry blockers 
had no effect on cardiac beta-adrenoceptor density. Thus, 
diltiazem must interfere with the effects of cyclosporine A; 
however, the mechanism of this interaction isstill unknown. In 
this context, cyclosporine A induced an increase in renal 
sympathetic nerve activity in rats that was strongly associated 
with inhibition of calcineurin activity (47), the intracellular 
target of cyclosporine A, which binds the cyclosporine A-cy- 
clophilin complex in a calcium ion-dependent manner (48). 
However, calcineurin, which is localized not only in lymphoid 
tissues, but has also been found in neural tissues (49), is 
involved in transcriptional processes (48). Furthermore, cyclo- 
sporine A has been shown to enhance basal calcium ion influx 
and to augment angiotension II-stimulated influx of calcium 
ions in vascular smooth muscle cells (50,51) and to increase 
angiotensin II-induced vasoconstriction i  isolated rat aorta 
(21). Whether attenuation of these effects (cyclosporine A-in- 
duced calcium ion accumulation or inhibition of calcineurin- 
mediated transcriptional processes) by the calcium entry 
blocker diltiazem might be involved in its protective ffect 
against cyclosporine A-induced downregulation of cardiac 
betal-adrenoceptors remains to be elucidated. 
Conclusions. The results of the present study show that a 
therapeutically relevant dose of cyclosporine A caused selec- 
tive downregulation of cardiac betal-adrenoceptors in both 
spontaneously h pertensive (11) and normotensive rats. Be- 
cause this event can be prevented by the angiotensin- 
converting enzyme inhibitors enalapril and lisinopril, it might 
be due to the activating effects of cyclosporine A on the 
renin-angiotensin system or sympathetic nervous system, or 
both. The mechanism of the diltiazem-induced prevention of 
cyclosporine A-evoked betal-adrenoceptor d wnregulation is 
still unknown. 
Clinical implications. The present findings of a selective 
downregulation of cardiac betal-adrenoceptors by cyclospo- 
fine A and its prevention by angiotensin-converting e zyme 
inhibitors or diltiazem could have clinical implications. Human 
heart transplant recipients with long-term cyclosporine A 
therapy show the same pattern of selective betal-adrenoceptor 
downregulation with no change in beta2-adrenoceptor density 
with increasing time after transplantation (12-14). Moreover, 
it has recently been shown (52) that cyclosporine A also 
increases ympathetic activity in heart transplant recipients, 
and this might be enhanced because of the impaired cardio- 
pulmonary baroreflex activity in such patients. The develop- 
ment of hypertension i heart transplant recipients is a com- 
mon side effect of cyclosporine A that has been directly 
attributed to its administration (53). Thus, the present results 
suggest hat treatment of this form of hypertension with 
calcium-entry blockers (and, under certain circumstances, pos- 
sibly angiotensin-converting enzyme inhibitors) might be of 
benefit because they not only normalize blood pressure (8), but 
also may protect the transplanted heart against beta- 
adrenoceptor subtype redistribution. 
We are grateful to Dr. R. J. Summers, University of Melbourne for giving us 
access to his data before publication. 
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